title: Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.
abstract: BACKGROUND
  Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.
  
  
  METHODS
  Patients with advanced ACC were included in this phase II trial investigating the response to a combination of cisplatin (50 mg m(-2)) and docetaxel (60 mg m(-2)) administered with a 3-week interval.
  
  
  RESULTS
  Nineteen patients were included in this study. The response rate was 21% (95% CI: 3-39%). No patients obtained a complete response, 32% had stable disease, and 37% progressed while on treatment. The median progression-free survival (PFS) was 3 months (95% CI: 0.7-5.3 months) and 1 year PFS was 21% (95% CI: 3-39%). Median survival was 12.5 months (95% CI: 6-19 months). The predominant grade 3/4 toxicity was neutropenia (35%); febrile neutropenia occurred in 5% of cycles.
  
  
  CONCLUSIONS
  This study could not demonstrate that the combination of cisplatin and docetaxel has higher efficacy than other regimens reported in previous studies.
authors: Department of Oncology, Rigshospitalet, Copenhagen, Denmark. thomas.urup@rh.regionh.dk
authors: T
authors: T
authors: Urup
authors: W Z
authors: WZ
authors: Pawlak
authors: P M
authors: PM
authors: Petersen
authors: H
authors: H
authors: Pappot
authors: M
authors: M
authors: Rørth
authors: G
authors: G
authors: Daugaard
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018268:Adrenocortical Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
references: Cancer. 2002 May 1;94(9):2333-43
references: 12015757
references: World J Surg. 2001 Jul;25(7):891-7
references: 11572030
references: Chemotherapy. 1998 Mar-Apr;44(2):129-34
references: 9551244
references: Cancer. 2000 Mar 1;88(5):1159-65
references: 10699907
references: BJU Int. 2011 Nov;108(10):1546-54
references: 21883840
references: J Clin Endocrinol Metab. 2009 Jun;94(6):1853-78
references: 19494161
references: Ann Oncol. 2000 Jul;11(7):845-9
references: 10997812
references: World J Surg. 2006 May;30(5):872-8
references: 16680602
references: N Engl J Med. 2012 Jun 7;366(23):2189-97
references: 22551107
references: Horm Metab Res. 2008 May;40(5):302-5
references: 18491247
references: Nat Rev Endocrinol. 2011 Jun;7(6):323-35
references: 21386792
references: Br J Cancer. 2013 Feb 5;108(2):265-70
references: 23329236
references: Eur J Cancer. 2010 Mar;46(4):713-9
references: 20044246
references: Endocr Res. 1996 Nov;22(4):709-15
references: 8969931
references: Endocr Relat Cancer. 2005 Sep;12(3):657-66
references: 16172198